Madrigal Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Business context and period: Clinical-stage biopharmaceutical company developing resmetirom for NASH and other potential indications. This unaudited filing covers the quarter and six months ended June 30, 2021; dollar amounts below are in millions unless stated otherwise. Madrigal had no product revenue.
Financial results and position
- Q2 2021: R&D expense was $51.6 million, up 16% year over year; G&A was $10.1 million, up 79%. Operating loss was $61.7 million and net loss was $61.7 million, versus $49.0 million a year earlier. Basic and diluted loss per share was $3.72, versus $3.18.
- First half 2021: R&D expense was $97.4 million, up 25%; G&A was $17.3 million, up 69%. Operating loss was $114.7 million and net loss was $114.2 million, versus $85.2 million a year earlier. Loss per share was $7.05, versus $5.52.
- Cash flow, first half: Operating cash use was $90.3 million, compared with $54.8 million in 2020. Investing cash use was $60.8 million, largely reflecting purchases of marketable securities net of maturities and sales. Financing provided $130.6 million, mainly from ATM stock sales. Cash and cash equivalents declined $20.5 million to $33.5 million.
- Liquidity and balance sheet: Cash, cash equivalents, and marketable securities totaled $323.8 million at June 30, up from $284.1 million at year-end 2020. Total assets were $328.0 million; total liabilities were $57.3 million, including $55.2 million of accrued expenses and $1.0 million of lease liabilities. The filing reports no borrowings or other debt. Management said available funds were expected to support operations for more than one year from issuance of the statements.
- Margins: Not meaningful because the company had no revenue and reported operating losses. Interest income fell to $0.1 million in Q2 and $0.3 million for the first half, primarily due to lower interest rates.
Changes and operating developments
- Higher R&D spending reflected increased Phase 3 trial activity, headcount, and stock compensation. Higher G&A reflected commercial preparation, increased headcount, and stock compensation.
- First-half ATM sales generated $130.2 million in net proceeds from 1,087,126 shares, increasing common shares outstanding. A new ATM agreement authorized up to $200 million in additional sales; that amount remained unsold at June 30.
- On June 30, the company announced it had achieved target enrollment for MAESTRO-NASH to support a planned Subpart H accelerated-approval submission. MAESTRO-NAFLD-1 enrollment had exceeded its target, with approximately 1,300 patients enrolled overall.
Outlook, risks, and contingencies
- Management expects continued operating losses and substantial development spending, with R&D and potentially G&A expenses rising as programs advance and commercial preparation expands. The filing provides no quantified earnings or revenue guidance.
- Management may seek additional capital through equity or debt financing, collaborations, partnerships, or strategic transactions. Funding may not be available on acceptable terms; equity issuance may dilute shareholders and debt may impose restrictive covenants.
- Key risks include clinical-trial execution and enrollment, safety outcomes, regulatory approval, product development and commercialization, market acceptance and reimbursement, and financing needs. COVID-19 had no material adverse effect on the reported period’s results, MAESTRO-NAFLD-1, or liquidity, but continued to pose operational and trial uncertainties.
- Roche agreement obligations include $8 million of remaining regulatory milestones and a single-digit royalty range on future net sales of resmetirom products, subject to reductions. No additional milestones were achieved and there were no product sales in the period.
- No material pending legal proceedings were reported. The company reported no material changes to previously disclosed risk factors and no off-balance-sheet arrangements.
Important facts for investors to verify
- Progress, timing, and results for MAESTRO-NASH and MAESTRO-NAFLD-1, including endpoints, safety, and regulatory plans.
- Cash consumption relative to the $323.8 million liquidity balance and management’s stated runway, including the effect of future trial and commercial-preparation costs.
- ATM usage, remaining authorization, and resulting share dilution; common shares outstanding were 16,599,522 at June 30, 2021.
- Potential financing availability and the terms or dilution associated with future capital raises.
- Roche milestone and royalty obligations and any changes in clinical, regulatory, or commercialization risks.